ADVERTISEMENT

APhA Policy Manual

2016

Browse policies organized by category. Select a category to view the related policy statements.

17 categories • 45 policies

Advertising for Pharmacies

1 Policies
Investigation of Discount Card Issuer Practices

APhA encourages the Federal Trade Commission, the US attorney general or other appropriate agency to investigate misleading and deceptive marketing practices of issuers of discount cards.

Alcohol and Tobacco

1 Policies
Tobacco and Nicotine Use Data Entry Field in Pharmacy Patient Records

APhA supports standardizing patient records and clinical decision support tools (including pharmacy dispensing systems) to collect, document, and utilize information regarding the patient’s tobacco and nicotine use.

Continuing Education

5 Policies
Cross-Discipline Accreditation of Continuing Education

  1. APhA supports the acceptance, for pharmacy continuing education credit of relevant, quality programs offered by other health-related continuing education providers.
  2. APhA supports the acceptance of relevant programs offered by the Accreditation Council for Pharmacy Education (ACPE)-accredited providers to meet continuing education requirements in other health disciplines.

Continued Competence Assessment Examination

  1. APhA should develop, in cooperation with other state and national associations, a voluntary process for self-assessing pharmaceutical care competence.
  2. APhA opposes regulatory bodies utilizing continuing competence examinations as a requirement for renewal of a pharmacist’s license.
  3. APhA supports programs that measure and evaluate pharmacist competence based on established valid standards.

Continuing Education

APhA strongly endorses continuing education for pharmacists.

Use of Academic and Continuing Education Credit

  1. APhA supports the award of continuing education credit for the successful completion of academic credit courses within the scope of pharmacy practice under circumstances that preserve the integrity of both the academic and the continuing education credit.
  2. APhA endorses the development and implementation by colleges of pharmacy and other appropriate organizations, of standards and mechanisms by which academic credit can be awarded for successful completion of continuing education courses under circumstances that preserve the integrity of the academic credit.

Pharmacists’ Responsibility for Continuing Competence

APhA advocates that pharmacists maintain their professional competence throughout their professional careers.

Degree/Designation

1 Policies
Distance Education in First Professional Pharmacy Degree Programs

  1. Distance education components of first professional pharmacy degree programs must be constructed in a way to ensure socialization into the profession and understanding the ethos and essence of the profession, as such development is primarily derived through practical experience and interaction with faculty, colleagues, and patients.
  2. APhA expects the Accreditation Council for Pharmacy Education to develop, maintain, and enforce applicable standards to ensure students trained in distance education programs achieve the same educational and professional competencies as students in on-site programs.

Drug Names

1 Policies
Brand-Name Line Extensions

APhA opposes the use of the same brand name (or minor modifications of the same name) for prescription and nonprescription drug products containing different active ingredients.

General Health Care Organizations

2 Policies
Other Health Care Professional Organizations

APhA supports continuing collaboration with other health care and professional organizations.

The Joint Commission

  1. APhA supports increased interaction with The Joint Commission regarding accreditation standards and procedures pertaining to pharmacy and therapeutics.
  2. APhA supports pharmacy representation on appropriate The Joint Commission professional and technical advisory committees.

Hallucinogens

1 Policies
Removal of Hallucinogenic Solvents from Paints, Sprays, and Glues

APhA supports the denaturing of abused products containing hallucinogens by appropriate means, such as the addition of harmless chemicals with obnoxious scents or with the ability to produce nausea when the products are abused, but not when used as directed.

Licensure and Registration of Personnel

1 Policies
Continued Competence Assessment Examination

  1. APhA should develop, in cooperation with other state and national associations, a voluntary process for self-assessing pharmaceutical care competence.
  2. APhA opposes regulatory bodies utilizing continuing competence examinations as a requirement for renewal of a pharmacist’s license.
  3. APhA supports programs that measure and evaluate pharmacist competence based on established valid standards.

Licensure, Registration and Inspection of Facilities

2 Policies
Pharmacy Practice Accreditation

  1. APhA should lead the creation of consensus-based, pharmacy profession-developed accreditation standards and methods of evaluation to optimize the quality and safety of patient care and promote best practices.
  2. APhA urges that accrediting bodies use profession-developed standards for pharmacy.
  3. APhA supports only those pharmacy accreditation processes that are voluntary, transparent, consensus-based, reasonably executable, and affordable, while avoiding duplication and barriers to patient care.
  4. APhA opposes mandatory pharmacy accreditation.
  5. APhA shall assume the leadership role among stakeholders on the design and implementation of an appropriate process for any new pharmacy accrediting program.
  6. APhA supports the appropriate use of data gathered from pharmacy practice monitoring processes to facilitate the advancement of pharmacy practice and quality of patient care.

Pharmacy Compounding Accreditation

  1. APhA reaffirms the 1992 Compounding Activities of Pharmacists policy, which states that APhA affirms that compounding pursuant to or in anticipation of a prescription or diagnostic preparation order is an essential part of health care that is the prerogative of the pharmacist.
  2. APhA supports compounding as defined by the Pharmacy Compounding Accreditation Board (PCAB) as a means to meet patient drug therapy needs.
  3. APhA opposes compounding when identical medications are commercially and readily available in strength and dosage form to meet patient drug therapy needs.
  4. APhA asserts that compounding is subject to regulations and oversight from state boards of pharmacy. APhA urges state boards of pharmacy to identify and take appropriate action against entities who are illegally manufacturing medications under the guise of compounding.
  5. APhA supports accreditation of compounding sites by PCAB to ensure patient safety. APhA encourages state boards of pharmacy to recommend accreditation for those sites that engage in more than basic non-sterile compounding as defined by PCAB.
  6. APhA supports the development of education, training and recognition programs that enhance pharmacist and student pharmacist knowledge and skills to engage in compounding beyond basic, non-sterile preparations as defined by PCAB.
  7. APhA encourages the exploration of a specialty certification in compounding through the Board of Pharmaceutical Specialties (BPS).

New Payment Systems

1 Policies
APhA’s Role in the Development and Support of New Payment Systems

  1. APhA should continue its work with pharmacy benefits’ managers and other private and public payers to develop innovative pharmacy benefit designs and compensation strategies for pharmacists’ services.
  2. APhA will endorse benefit design concepts that recognize and compensate pharmacists for their cognitive services to maximize therapeutic outcomes.

Other Public Health Issues

2 Policies
Fluoridation of Water Supplies

APhA reaffirms its 1954 position in support of appropriate fluoridation of water supplies and encourage pharmacists to assist in implementing such programs in their local communities.

Reye Syndrome

APhA supports all initiatives which enhance public education about the potential relationship between Reye Syndrome and oral and rectal salicylate-containing products, including settings where pharmacists are not available for consultation.

Pharmacy School Curriculum

3 Policies
Professional Development of Student Pharmacists

  1. APhA believes that it is essential to integrate professionalism throughout a student pharmacist’s educational experience.
  2. APhA will assist schools and colleges of pharmacy to develop and utilize recruitment materials that emphasize the professional role and responsibilities associated with the provision of pharmaceutical care.
  3. APhA supports schools and colleges of pharmacy interviewing candidates during the admissions process to assess their characteristics for the potential for development of professional attitudes and behaviors.
  4. APhA recommends that schools and colleges of pharmacy administer the model pledge of professionalism, as developed by the APhA-ASP/American Association of Colleges of Pharmacy Council of Deans Task Force on Professionalism, to all student pharmacists.
  5. APhA encourages schools and colleges of pharmacy and the American Association of Colleges of Pharmacy to develop and implement ongoing programs for faculty, staff, preceptors, and other mentors to enhance their ability to serve as role models and teach professionalism.
  6. APhA supports the continuation of a forum for faculty, students, preceptors, and others to establish and foster mentor relationships.

Payment System Reform Curriculum

APhA encourages the colleges and schools of pharmacy to incorporate the concept of payment system reform throughout the curricula for all professional programs, and should work with pharmacy organizations to ensure the integration of these concepts into practitioners’ continuing development.

Primary and Secondary Education in Science, Mathematics, and English

APhA supports efforts to improve education at the primary and secondary school levels, particularly in the areas of science, mathematics, and English.

Physicians

2 Policies
Pharmacists and Other Health Practitioners: Relationships and Compensation Among Health Care Practitioners

APhA opposes any method that provides an inappropriate sharing of compensation between the prescriber and dispenser.

Guidelines for Physician Ownership

APhA supports efforts to develop guidelines on physician ownership of pharmacies due to the inherent conflict of interest.

Prescription & NonPrescription Drugs

1 Policies
Prescription Drug Advertising

APhA does not oppose the dissemination of price information to patients, by advertising or by any other means.

Therapeutic Equivalence

1 Policies
Pharmaceutical Alternates

APhA supports recognition of the pharmacist’s role in the selection of pharmaceutical alternates (i.e., drug products containing the same therapeutic moiety, but differing in salt, ester, or comparable physical/chemical form or differing in dosage form)

Third Party and Prepaid Programs

1 Policies
The Scientific Implications of Health Care Reform

  1. APhA advocates that the public and private sectors maintain or increase their level of commitment to ensure adequate resources for both basic and applied research within a reformed health care system.
  2. APhA encourages the public and private research communities to preferentially expend resources for the discovery and development of new drugs and technologies that provide substantive, innovative therapeutic advances.
  3. APhA advocates an increased emphasis on outcomes research in all areas of health services, including drug and disease-specific research encompassing clinical, economic, and humanistic dimensions (e.g., quality of life, patient satisfaction, ethics) and advocates for action related to conclusions for such research.
  4. APhA encourages interdisciplinary collaboration in research efforts within and between the public and private research communities.

Model Disaster Plan for Pharmacists

  1. The committee recommends that APhA develop a disaster plan for the guidance of pharmacy organizations in responding to the needs of pharmacists who experience losses from disasters and that this model plan be disseminated to state associations for their reference.
  2. The committee recommends that APhA cooperate with associations representing pharmaceutical manufacturers, wholesale distributors, and others in the pharmaceutical supply system in developing a mechanism to facilitate the communication of information about the losses incurred by pharmacists as a result of disasters. Those firms that make it a practice to replace uninsured losses of inventories of their products could do so promptly and efficiently so that normal pharmaceutical services to the affected community are resumed as soon as possible.

Issuing of Drugs by Non-Pharmacists

APhA supports issuing drug products to patients by non-pharmacists under the control and direction of pharmacists.

Pharmacy Personnel With Impairments That Affect Practice

  1. APhA advocates that pharmacy personnel should not work while subject to physical or mental impairment due to substances that might adversely affect their abilities to function properly in their professional capacities.
  2. APhA supports establishment of counseling, treatment, prevention, and rehabilitation programs for pharmacy personnel who are subject to physical or mental impairment due to substances that might adversely affect their abilities to function in their professional capacities.
  3. APhA encourages employers to provide support to pharmacy personnel in need of medical leave to address mental health and substance use disorders.
  4. APhA encourages employers to provide pharmacy personnel time away from work that facilitates appropriate care for mental health or substance use disorders without retaliation.
  5. APhA advocates for timely referrals to health professional recovery programs when available, even in instances where disciplinary actions may be considered.
  6. APhA encourages employers to actively support pharmacy personnel in recovery for substance use disorder by offering employment opportunities and non-dispensing roles as they reintegrate into the workforce.

Funding for Pharmacist Recovery Programs

APhA supports and encourages a cooperative effort among state and national pharmacy associations, state boards of pharmacy, and state legislative bodies to authorize, develop, implement and maintain mechanisms for the comprehensive funding of state recovery programs for pharmacists, student pharmacists and pharmacy technicians.

Drug Enforcement Agency Employment Waiver

APhA urges the Drug Enforcement Administration, in processing employment waiver requests, to defer to the decisions of state boards of pharmacy related to the licensure of pharmacists suffering from alcohol and other chemical dependencies.

Drug Testing in the Workplace

APhA endorses the concept of the "Drug–Free Workplace" and recommends that, where drug testing is performed in the workplace, it be conducted in conjunction with an employee assistance program.

Single-Dose Containers for Parenteral Use

APhA supports packaging all drugs intended for parenteral use in humans in single-dose containers, except where clearly not feasible.

The Scientific Implications of Health Care Reform

  1. APhA advocates that the public and private sectors maintain or increase their level of commitment to ensure adequate resources for both basic and applied research within a reformed health care system.
  2. APhA encourages the public and private research communities to preferentially expend resources for the discovery and development of new drugs and technologies that provide substantive, innovative therapeutic advances.
  3. APhA advocates an increased emphasis on outcomes research in all areas of health services, including drug and disease-specific research encompassing clinical, economic, and humanistic dimensions (e.g., quality of life, patient satisfaction, ethics) and advocates for action related to conclusions for such research.
  4. APhA encourages interdisciplinary collaboration in research efforts within and between the public and private research communities.

Labeling and Measurement of Oral Liquid Medications

  1. APhA supports the use of the milliliter (mL) as the standard unit of measure for oral liquid medications.
  2. APhA encourages the mandatory use of leading zeros before the decimal point for amounts of less than one on prescription-container labels for oral liquid medications.
  3. APhA discourages the use of trailing zeros after the decimal point for amounts greater than one on prescription-container labels for oral liquid medications.
  4. APhA supports access to and universal availability of dosing devices with numeric graduations that correspond to the unit of measure that is on the container’s label for oral liquid medications.

Labeling and Measurement of Oral Liquid Medications

  1. APhA supports the use of the milliliter (mL) as the standard unit of measure for oral liquid medications.
  2. APhA encourages the mandatory use of leading zeros before the decimal point for amounts of less than one on prescription-container labels for oral liquid medications.
  3. APhA discourages the use of trailing zeros after the decimal point for amounts greater than one on prescription-container labels for oral liquid medications.
  4. APhA supports access to and universal availability of dosing devices with numeric graduations that correspond to the unit of measure that is on the container’s label for oral liquid medications.

Child Abuse Reporting

APhA urges pharmacists to report all suspected cases of child abuse to proper authorities.

Cost Effectiveness of Drug Products and Pharmacy Services

APhA supports the development of programs that educate pharmacy’s several publics about the cost effectiveness of drug products and related comprehensive pharmacists services.

Labeling and Measurement of Oral Liquid Medications

  1. APhA supports the use of the milliliter (mL) as the standard unit of measure for oral liquid medications.
  2. APhA encourages the mandatory use of leading zeros before the decimal point for amounts of less than one on prescription-container labels for oral liquid medications.
  3. APhA discourages the use of trailing zeros after the decimal point for amounts greater than one on prescription-container labels for oral liquid medications.
  4. APhA supports access to and universal availability of dosing devices with numeric graduations that correspond to the unit of measure that is on the container’s label for oral liquid medications.

Pharmacy Practice Accreditation

  1. APhA should lead the creation of consensus-based, pharmacy profession-developed accreditation standards and methods of evaluation to optimize the quality and safety of patient care and promote best practices.
  2. APhA urges that accrediting bodies use profession-developed standards for pharmacy.
  3. APhA supports only those pharmacy accreditation processes that are voluntary, transparent, consensus-based, reasonably executable, and affordable, while avoiding duplication and barriers to patient care.
  4. APhA opposes mandatory pharmacy accreditation.
  5. APhA shall assume the leadership role among stakeholders on the design and implementation of an appropriate process for any new pharmacy accrediting program.
  6. APhA supports the appropriate use of data gathered from pharmacy practice monitoring processes to facilitate the advancement of pharmacy practice and quality of patient care.

Pharmacy Compounding Accreditation

  1. APhA reaffirms the 1992 Compounding Activities of Pharmacists policy, which states that APhA affirms that compounding pursuant to or in anticipation of a prescription or diagnostic preparation order is an essential part of health care that is the prerogative of the pharmacist.
  2. APhA supports compounding as defined by the Pharmacy Compounding Accreditation Board (PCAB) as a means to meet patient drug therapy needs.
  3. APhA opposes compounding when identical medications are commercially and readily available in strength and dosage form to meet patient drug therapy needs.
  4. APhA asserts that compounding is subject to regulations and oversight from state boards of pharmacy. APhA urges state boards of pharmacy to identify and take appropriate action against entities who are illegally manufacturing medications under the guise of compounding.
  5. APhA supports accreditation of compounding sites by PCAB to ensure patient safety. APhA encourages state boards of pharmacy to recommend accreditation for those sites that engage in more than basic non-sterile compounding as defined by PCAB.
  6. APhA supports the development of education, training and recognition programs that enhance pharmacist and student pharmacist knowledge and skills to engage in compounding beyond basic, non-sterile preparations as defined by PCAB.
  7. APhA encourages the exploration of a specialty certification in compounding through the Board of Pharmaceutical Specialties (BPS).

Quality Assurance and Improvement in Pharmacy Practice

  1. APhA recommends that all pharmacists incorporate principles and tools available to continually improve the quality of patient care and management activities in their practices.
  2. APhA recommends that content on principles and tools available to continually improve the quality of patient care and management practices be incorporated into pharmacy school curricula and into post-graduate education for pharmacists.
  3. APhA supports appropriate evaluation and recognition of providers of pharmaceutical care.

Measuring the Quality of Patient Care

  1. APhA believes that quality assessment measures must evaluate the accessibility, acceptability, and technical quality of pharmacy services, as well as the patient-centered and economic outcomes of patient care. These measures must consider the perspectives of patients, pharmacists, and other health care providers.
  2. APhA believes quality assessment measures of patient care should be tested for validity and reliability in various pharmacy practice settings prior to widespread application.
  3. APhA should develop tools and/or programs that enable pharmacists to apply quality assessment measures to their delivery of patient care.
  4. APhA should promote efforts to educate patients, pharmacists, other health care providers, payers, policy makers, and other interested parties on the appropriate use of quality assessment measures to evaluate and improve the delivery of patient care.

Pharmacy Practice Accreditation

  1. APhA should lead the creation of consensus-based, pharmacy profession-developed accreditation standards and methods of evaluation to optimize the quality and safety of patient care and promote best practices.
  2. APhA urges that accrediting bodies use profession-developed standards for pharmacy.
  3. APhA supports only those pharmacy accreditation processes that are voluntary, transparent, consensus-based, reasonably executable, and affordable, while avoiding duplication and barriers to patient care.
  4. APhA opposes mandatory pharmacy accreditation.
  5. APhA shall assume the leadership role among stakeholders on the design and implementation of an appropriate process for any new pharmacy accrediting program.
  6. APhA supports the appropriate use of data gathered from pharmacy practice monitoring processes to facilitate the advancement of pharmacy practice and quality of patient care.

Quality Assurance and Improvement in Pharmacy Practice

  1. APhA recommends that all pharmacists incorporate principles and tools available to continually improve the quality of patient care and management activities in their practices.
  2. APhA recommends that content on principles and tools available to continually improve the quality of patient care and management practices be incorporated into pharmacy school curricula and into post-graduate education for pharmacists.
  3. APhA supports appropriate evaluation and recognition of providers of pharmaceutical care.

Advertisement
Advertisement